Zhonghua Li

Zhonghua Li

Auto-generated profile, based on publicly available information

Zhonghua Li

Academy of Chinese Medical Sciences, Henan University of Chinese Medicine

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ZLZhonghua Li
Zhonghua Li
ZZZhenqiang Zhang
Zhenqiang Zhang
BYBin Yu
Bin Yu

1 December 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ZLZhonghua Li
Zhonghua Li
TQTingting Qin
Tingting Qin
ZLZhongrui Li
Zhongrui Li
XZXuan Zhao
Xuan Zhao
XZXinhui Zhang
Xinhui Zhang
ZZZhenqiang Zhang
Zhenqiang Zhang

1 February 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ZLZhong-Hua Li
Zhong-Hua Li
JMJin-Lian Ma
Jin-Lian Ma
GLGai-Zhi Liu
Gai-Zhi Liu
XZXin-Hui Zhang
Xin-Hui Zhang
TQTing-Ting Qin
Ting-Ting Qin
ZZZhenqiang Zhang
Zhenqiang Zhang

25 October 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YLYu Li
Yu Li
YZYuanyuan Zhao
Yuanyuan Zhao
XLXiaona Li
Xiaona Li
LZLiuqun Zhai
Liuqun Zhai
HZHua Zheng
Hua Zheng
ZLZhonghua Li
Zhonghua Li
Alzheimer’s disease (AD) is a common chronic neurodegenerative disease characterized by cognitive learning and memory impairments, however, current treatments only provide symptomatic relief. Lysine-specific demethylase 1 (LSD1), regulating the homeostasis of histone methylation, plays an important role in the pathogenesis of many neurodegenerative disorders. LSD1 functions in regulating gene expression via transcriptional repression or activation, and is involved in initiation and progression of AD. Pharmacological inhibition of LSD1 has shown promising therapeutic benefits for AD treatment. In this review, we attempt to elaborate on the role of LSD1 in some aspects of AD including neuroinflammation, autophagy, neurotransmitters, ferroptosis, tau protein, as well as LSD1 inhibitors under clinical assessments for AD treatment.

22 April 2025 in ACS Omega
Verified
Journal Article
Open access
XLXiaofang Li
Xiaofang Li
YSYunfang Su
Yunfang Su
NLNa Lin
Na Lin
YCYujie Chen
Yujie Chen
ZLZhonghua Li
Zhonghua Li
HZHua Hui Zeng
Hua Hui Zeng
Pancreatic cancer (PC), known as the ″king of cancer," is a prevalent and aggressive form of malignant tumor affecting the digestive tract. Triptolide (TP), an epoxidized diterpenoid lactone extracted from Tripterygium wilfordii, shows promising antitumor activity. However, the systemic toxicity and poor water solubility of TP inhibit its clinical application. In this work, Lycium barbarum polysaccharide (LBP)-modified selenium nanoparticles (SeNPs), capable of reducing severe toxicity and enhancing solubility, have been designed, synthesized, and applied for the treatment of PC. In vitro release results revealed that TP showed an acid-dependent and sustained-release effect. In Pan02 cells, the IC50 values of TP and LBP-SeNPs@TP were 26.03 ± 2.82 ng/mL and 11.80 ± 2.64 ng/mL, respectively. Similarly, the IC50 values of TP and LBP-SeNPs@TP for L02 cells were 15.76 ± 0.58 ng/mL and 32.73 ± 2.61 ng/mL, suggesting enhanced antitumor efficacy along with reduced toxicity. Flow cytometry analysis demonstrated that LBP-SeNPs@TP exerted the most potent apoptotic effect, achieving an early apoptosis rate of 24.5% and a late apoptosis rate of 45.3%. Notably, the mitochondrial membrane potential was significantly reduced, while ROS production was increased in the LBP-SeNPs@TP group. LBP-SeNPs@TP could significantly inhibit tumor growth while minimizing toxicity. RT-qPCR analysis demonstrated that LBP-SeNPs@TP upregulated the mRNA expression of Bax, Cyt C, and Caspase-3, while downregulating Bcl-2 expression in vitro and in vivo. The immunohistochemical analysis of the tumor tissue further confirmed these results. Overall, LBP-SeNPs emerge as a promising platform for poorly soluble drugs, offering a potential therapeutic approach for pancreatic cancer.

30 March 2023 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ZLZhonghua Li
Zhonghua Li
YYYong Yuan
Yong Yuan
PWPan Wang
Pan Wang
ZZZijuan Zhang
Zijuan Zhang
HMHuifen Ma
Huifen Ma
ZZZhenqiang Zhang
Zhenqiang Zhang